Internal Medicine

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.

On April 19, 2023, an expert clinical decision pathway and scientific statement were published simultaneously in JACC. Both of these documents were aimed at providing an overview of heart failure with preserved ejection fraction, including diagnosis and management, based on contemporary evidence.

A qualitative study shows nurses at an urban, academic emergency department vary on whether behavioral flagging results in safer patient interactions.

An analysis of real-world data suggests intravitreal injection of biosimilar ranibizumab in a loading dose followed by a PRN protocol is a viable strategy for treating patients with nAMD.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

New data suggest 10 years of consecutive poverty is a greater risk factor for death than dementia, obesity and stroke among Americans.

Black primary care physicians are now represented in more than 40% of US counties. A new study links the growth to improved Black individual health.

A systematic review and meta-analysis detail the unadjusted odds of developing chemotherapy-related cardiotoxicity among patients who are Black or of African ancestry relative to their White counterparts.

The top 10 most popular FDA approval articles from the first quarter of 2023, with an additional spotlight on other top regulatory news from the first 3 months of the year.

April 7, 2023 marks the 75th anniversary of the WHO’s definition of health—a concept that experts point out is yet to be achieved, and faces many modern hurdles.

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken a median 3.5 years to complete since 2012.

An entire population gradually loses their vision, impeding everyday activities like driving in the dark, while investigators explore gene therapies in a race against the clock.

A new cohort study suggested the number of days per week taking 8000 steps or more was associated with a decreased risk of all-cause and cardiovascular mortality.

An analysis of more than 9000 adults aged 40 and older without known cardiovascular disease is shedding new light on the risk of myocardial infarction and mortality associated with subclinical coronary atherosclerosis.

As the US tries to move on from the pandemic, patients with long COVID-19 are fighting to regain normalcy while clinicians improve care plans and researchers search for answers.

On March 24, the US Food and Drug Administration announced a proposed rule changes aimed at promoting use of safe and suitable salt substitutes with the intent of improving nutrition and reducing chronic illness.

Most respondents in the multsite survey study preferred to immediately receive newly released test results via an online patient portal, despite receiving results prior to discussion with a health care provider.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.

New cohort analysis data show women with fibromyalgia are at an increased risk of depression—which is also correlated with a worse life expectancy over 8 years.

Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo.

The approval for omaveloxolone was supported by open-label data showing benefit of care for up to 3 years.

Verrica Pharmaceutical's drug-device combination will be decided upon as potentially the first molluscum drug in July.

Patients' perceptions of the effectiveness and necessity of allopurinol for gout treatment proved to be strong factors influencing intentional adherence.

A cohort study of 1.9 million infants links exposure to fine particulate matter (PM2.5) to an increased risk of emergency department visits during the first year of life, with preterm and full-term infants being most susceptible during their fourth and fifth months.

Phase 2 trial shows iron hydroxide adipate tartrate (IHAT) is non-inferior to ferrous sulfate (FeSO4) in correcting iron deficiency and hemoglobin response, with a lower incidence of moderate-severe diarrhea.